Marker Therapeutics Inc (MRKR)

[microcapbiotech]

For the TPIV200 ovarian cancer study.

"Marker had previously projected the initiation of its interim analysis to begin in Q4 2018, triggered by the 50th patient to progress following treatment. Despite faster than expected enrollment of patients in this study, as of the end of December fewer than 50 patients had progressive disease. As a result, Marker now expects to reach its planned interim analysis trigger by end of the second quarter of 2019, with interim data reported by year end."

Doesn't that just mean that the interim analysis is delayed because patients are DOING BETTER than they expected?